MYL4 expression was significantly higher in CDC-treated PAH animals compared to PBS-treated control and may have contributed to the enhanced function observed via TAPSE by preserving cardiomyocyte viability and enhancing contractility, but without driving further muscle fiber hypertrophy. This evidence concerns the gene MYL4 and pulmonary arterial hypertension.